Claims for Patent: 10,576,154

Summary for Patent: 10,576,154

Title:	Semifluorinated alkane compositions
Abstract:	The invention provides novel compositions comprising semifluorinated alkanes and at least one compound sensitive or prone to oxidation. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue. The invention further provides kits comprising such compositions.
Inventor(s):	Günther Bernhard, Scherer Dieter, Pettigrew Anthony, Theisinger Bastian, Theisinger Sonja
Assignee:	NOVALIQ GMBH
Application Number:	US16041317
Patent Claims:	1. A method of treating a disease or disorder of the eye wherein the disease or disorder is either (a) meibomian gland dysfunction and symptoms or conditions associated therewith or (b) keratoconjunctivitis sicca (dry eye) and symptoms or conditions associated therewith , in a patient in need of such treatment , comprising topically administering an effective amount of a stable liquid composition to an eye or ophthalmic tissue of the patient ,{'sub': 2', '2, 'wherein the composition consists of a semifluorinated alkane of the formula F(CF)n(CH)mH, wherein n is an integer from 3 to 8 and m is an integer from 3 to 10, and optionally one or more excipients.'}2. The method according to claim 1 , wherein the semifluorinated alkane is selected from F(CF)(CH)H claim 1 , F(CF)(CH)H claim 1 , F(CF)(CH)H claim 1 , F(CF)(CH)H claim 1 , F(CF)(CH)H claim 1 , F(CF)(CH)H claim 1 , and F(CF)(CH)H.3. The method according to claim 1 , wherein the semifluorinated alkane is F(CF)(CH)H.4. The method according to claim 1 , wherein the composition consists of F(CF)(CH)H.5. The method according to claim 1 , wherein the disease or disorder is meibomian gland dysfunction and wherein the symptom associated with meibomian gland dysfunction is selected from itchiness claim 1 , redness claim 1 , swelling claim 1 , pain or soreness claim 1 , discharge accumulation or crusting at the lid margins.6. The method according to claim 1 , wherein the disease or disorder is meibomian gland dysfunction and wherein the meibomian gland dysfunction is characterized by gland duct obstructions and/or qualitative and/or quantitative changes to the secretions of the glands.7. The method according to claim 1 , wherein the composition is topically administered to the cornea claim 1 , the conjunctiva or to the upper or lower eye lid margins claim 1 , meibomian gland ducts claim 1 , eye lashes or any area of the eye or eye lid anatomy.8. The method according to claim 1 , wherein the disease or disorder is keratoconjunctivitis sicca and the condition associated with keratoconjunctivitis sicca is selected from Sjogren syndrome claim 1 , lacrimal gland insufficiency claim 1 , meibomian gland disease and meibomian gland dysfunction.9. The method according to claim 1 , wherein the disease or disorder is keratoconjunctivitis sicca and the symptom associated with keratoconjunctivitis sicca is selected from dry claim 1 , scratchy claim 1 , gritty claim 1 , or sandy feeling in the eye; foreign body sensation; pain or soreness; stinging or burning; itching; increased blinking; eye fatigue; photophobia; blurry vision; redness; mucus discharge; contact lens intolerance; excessive reflex tearing.10. The method according to claim 1 , wherein the disease or disorder is keratoconjunctivitis sicca and the condition associated with keratoconjunctivitis sicca is meibomian gland dysfunction and wherein the composition consists of F(CF)(CH)H.11. The method according to claim 1 , wherein the disease or disorder is meibomian gland dysfunction and the composition consists of F(CF)(CH)H.12. The method according to claim 1 , wherein the disease or disorder is keratoconjunctivitis sicca and the composition consists of F(CF)(CH)H.13. The method according to claim 1 , wherein the composition consists of the semifluorinated alkane and one or more excipients selected from the group consisting of lipids claim 1 , oils claim 1 , lubricants claim 1 , lipophilic vitamins claim 1 , viscosity agents claim 1 , antioxidants claim 1 , surfactants claim 1 , and mixtures thereof.14. The method according to claim 13 , wherein the one or more excipients are selected from triglyceride oils claim 13 , mineral oil claim 13 , medium chain triglycerides (MCT) claim 13 , oily fatty acids claim 13 , isopropyl myristate claim 13 , oily fatty alcohols claim 13 , esters of sorbitol and fatty acids claim 13 , oily sucrose esters claim 13 , oily cholesterol esters claim 13 , oily wax esters claim 13 , glycerophospholipids claim 13 , sphingolipids claim 13 , and any oily substance which is physiologically tolerated by the eye.15. The method according to claim 14 , wherein the triglyceride oils are selected from soybean oil claim 14 , olive oil claim 14 , sesame oil claim 14 , cotton seed oil claim 14 , castor oil claim 14 , and sweet almond oil claim 14 , and wherein the mineral oil is selected from petrolatum and liquid paraffin.16. The method according to claim 1 , wherein the disease or disorder is keratoconjunctivitis sicca claim 1 , and wherein the direct or indirect cause of the keratoconjunctivitis sicca is meibomian gland dysfunction.17. The method according to claim 1 , wherein the disease or disorder is keratoconjunctivitis sicca claim 1 , and wherein the symptom or condition associated therewith is selected from aqueous deficient dry eye disease or evaporative dry eye disease.18. The method according to claim 1 , wherein the disease or disorder is meibomian gland dysfunction and wherein the meibomian gland dysfunction is characterized by abnormal claim 1 , reduced or increased delivery of lipids to the tear film.19. The method according to claim 1 , wherein the disease or disorder is keratoconjunctivitis sicca and wherein the keratoconjunctivitis sicca is characterized by abnormal claim 1 , reduced or increased delivery of lipids to the tear film.